Top

Published in:

01-12-2011 | Review

Epigenetics in breast cancer: what's new?

Authors: Yi Huang, Shweta Nayak, Rachel Jankowitz, Nancy E Davidson, Steffi Oesterreich

Published in: Breast Cancer Research | Issue 6/2011

Abstract

Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expression. The present review will focus on methylation and demethylation of histones. While the acetylation of histones has been at the forefront of well-characterized post-translational modifications of histones, including the development of inhibitors targeting de-acetylating enzymes, the past few years have witnessed a dramatic increase in knowledge regarding the role of histone methylation/demethylation. This is an exciting and rapidly evolving area of research, with much promise for potential clinical intervention in several cancers including breast cancer. We also summarize efforts to identity DNA methylation signatures that could be prognostic and/or predictive markers in breast cancer, focusing on recent studies using genome-wide approaches. Finally, we briefly review the efforts made by both the National Institutes of Health Epigenome Project and The Cancer Genome Atlas, especially highlighting the study of breast cancer epigenetics, exciting technological advances, potential roadblocks, and future directions.

Available only for authorised users

Jenuwein T, Allis CD: Translating the histone code. Science. 2001, 293: 1074-1080. 10.1126/science.1063127.CrossRefPubMed

Jones PA, Baylin SB: The epigenomics of cancer. Cell. 2007, 128: 683-692. 10.1016/j.cell.2007.01.029.CrossRefPubMedPubMedCentral

Stearns V, Zhou Q, Davidson NE: Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007, 25: 659-665. 10.1080/07357900701719234.CrossRefPubMed

Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6: 38-51. 10.1038/nrc1779.CrossRefPubMed

Dokmanovic M, Marks PA: Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005, 96: 293-304. 10.1002/jcb.20532.CrossRefPubMed

Marks PA, Richon VM, Miller T, Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res. 2004, 91: 137-168.CrossRefPubMed

Ficner R: Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem. 2009, 9: 235-240. 10.2174/156802609788085304.CrossRefPubMed

Marson CM: Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem. 2009, 9: 661-692.CrossRefPubMed

Khan O, La Thangue NB: Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol. 2008, 5: 714-726. 10.1038/ncponc1238.CrossRefPubMed

10.

Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003, 81: 177-186. 10.1023/A:1026146524737.CrossRefPubMed

11.

Zhou Q, Atadja P, Davidson NE: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther. 2007, 6: 64-69. 10.4161/cbt.6.1.3549.CrossRefPubMed

12.

Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000, 60: 6890-6894.PubMed

13.

Sharma D, Saxena NK, Davidson NE, Vertino PM: Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifenbound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006, 66: 6370-6378. 10.1158/0008-5472.CAN-06-0402.CrossRefPubMedPubMedCentral

14.

Pathiraja TN, Shetty TB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S: Progesterone receptor isoform-specific promoter methylation - Association of PRA methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011, 17: 4177-4186. 10.1158/1078-0432.CCR-10-2950.CrossRefPubMedPubMedCentral

15.

Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG, Baylin SB: Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006, 2: e40-10.1371/journal.pgen.0020040.CrossRefPubMedPubMedCentral

16.

ClinicalTrials.gov. [http://clinicaltrials.gov]

17.

Pathiraja TN, Stearns V, Oesterreich S: Epigenetic regulation in estrogen receptor positive breast cancer - role in treatment response. J Mammary Gland Biol Neoplasia. 2010, 15: 35-47. 10.1007/s10911-010-9166-0.CrossRefPubMedPubMedCentral

18.

Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21: 103-107. 10.1038/5047.CrossRefPubMed

19.

Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003, 63: 7089-7093.PubMed

20.

Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Baylin SB, Reed MD, Tellez CS, March TH: Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 2011, 71: 454-462. 10.1158/0008-5472.CAN-10-3184.CrossRefPubMedPubMedCentral

21.

Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, Di GH, Shen ZZ, Shao ZM: ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008, 134: 883-890. 10.1007/s00432-008-0354-x.CrossRefPubMed

22.

Gore SD: Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw. 2006, 4: 83-90.PubMed

23.

Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky SA, Brock MV, Herman JG, Baylin SB, Rudin CM: Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC). J Clin Oncol. 2008, 26 (May 20 suppl): abstract 19036-

24.

Martin C, Zhang Y: The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005, 6: 838-849. 10.1038/nrm1761.CrossRefPubMed

25.

Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell. 2007, 128: 735-745. 10.1016/j.cell.2007.02.009.CrossRefPubMed

26.

Baylin S, Ohm J: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006, 6: 107-116. 10.1038/nrc1799.CrossRefPubMed

27.

Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA. 2005, 102: 1859-1864. 10.1073/pnas.0409875102.CrossRefPubMedPubMedCentral

28.

van der Vlag J, Otte AP: Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999, 23: 474-478. 10.1038/70602.CrossRefPubMed

29.

Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003, 100: 11606-11611. 10.1073/pnas.1933744100.CrossRefPubMedPubMedCentral

30.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA: Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006, 12: 1168-1174. 10.1158/1078-0432.CCR-05-1533.CrossRefPubMed

31.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006, 24: 268-273.CrossRefPubMed

32.

Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011, 19: 86-100. 10.1016/j.ccr.2010.10.035.CrossRefPubMedPubMedCentral

33.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004, 119: 941-953. 10.1016/j.cell.2004.12.012.CrossRefPubMed

34.

Lee MG, Wynder C, Cooch N, Shiekhattar R: An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005, 437: 432-435.PubMed

35.

Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010, 31: 512-520. 10.1093/carcin/bgp324.CrossRefPubMed

36.

Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, Ju BG, Ohgi KA, Wang J, Escoubet-Lozach L, Rose DW, Glass CK, Fu XD, Rosenfeld MG: Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell. 2007, 128: 505-518. 10.1016/j.cell.2006.12.038.CrossRefPubMedPubMedCentral

37.

Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV: DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008, 319: 202-206. 10.1126/science.1147674.CrossRefPubMed

38.

Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE: Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat. 2011, [Epub ahead of print]

39.

Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature. 2007, 449: 105-108. 10.1038/nature06092.CrossRefPubMed

40.

Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E, Chen T: The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet. 2009, 41: 125-129. 10.1038/ng.268.CrossRefPubMed

41.

Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, Eggert A, Buettner R, Kirfel J: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009, 69: 2065-2071.CrossRefPubMed

42.

Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y: The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 2006, 442: 312-316. 10.1038/nature04853.CrossRefPubMed

43.

Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006, 125: 483-495. 10.1016/j.cell.2006.03.027.CrossRefPubMed

44.

Chen Z, Zang J, Whetstine J, Hong X, Davrazou F, Kutateladze TG, Simpson M, Mao Q, Pan CH, Dai S, Hagman J, Hansen K, Shi Y, Zhang G: Structural insights into histone demethylation by JMJD2 family members. Cell. 2006, 125: 691-702. 10.1016/j.cell.2006.04.024.CrossRefPubMed

45.

Yamane K, Tateishi K, RKlose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y: PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007, 25: 801-812. 10.1016/j.molcel.2007.03.001.CrossRefPubMed

46.

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010, 141: 69-80. 10.1016/j.cell.2010.02.027.CrossRefPubMedPubMedCentral

47.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010, 363: 1532-1543. 10.1056/NEJMoa1008433.CrossRefPubMedPubMedCentral

48.

Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A: Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol. 2005, 1: 143-145.CrossRefPubMed

49.

Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21: 1050-1063. 10.1101/gad.1524107.CrossRefPubMedPubMedCentral

50.

Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y: Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006, 97: 113-118. 10.1111/j.1349-7006.2006.00146.x.CrossRefPubMed

51.

Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T: Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life. 2010, 62: 194-199.CrossRefPubMed

52.

Lee M, Wynder C, Schmidt D, McCafferty D, Shiekhattar R: Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006, 13: 563-567. 10.1016/j.chembiol.2006.05.004.CrossRefPubMed

53.

Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A, Gunther T, Buettner R, Schule R: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005, 437: 436-439.PubMed

54.

Huang Y, Greene E, Stewart TM, Goodwin AC, Baylin SB, Woster PM, Casero RA: Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA. 2007, 104: 8023-8028. 10.1073/pnas.0700720104.CrossRefPubMedPubMedCentral

55.

Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, ones RJ, Woster PM Casero Jr RA: Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res. 2009, 15: 7217-7228. 10.1158/1078-0432.CCR-09-1293.CrossRefPubMedPubMedCentral

56.

Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA: Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids. 2011, [Epub ahead of print]

57.

Chen Z, Zang J, Kappler J, Hong X, Crawford F, Wang Q, Lan F, Jiang C, Whetstine J, Dai S, Hansen K, Shi Y, Zhang G: Structural basis of the recognition of a methylated histone tail by JMJD2A. Proc Natl Acad Sci USA. 2007, 104: 10818-10823. 10.1073/pnas.0704525104.CrossRefPubMedPubMedCentral

58.

Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M: Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010, 12: R36-10.1186/bcr2590.CrossRefPubMedPubMedCentral

59.

60.

Catteau A, Morris JR: BRCA1 methylation: a significant role in tumour development?. Semin Cancer Biol. 2002, 12: 359-371. 10.1016/S1044-579X(02)00056-1.CrossRefPubMed

61.

Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92: 564-569. 10.1093/jnci/92.7.564.CrossRefPubMed

62.

Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD, Jeddeloh JA: Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One. 2007, 2: e1314-10.1371/journal.pone.0001314.CrossRefPubMedPubMedCentral

63.

Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A, Ordway JM, McCombie WR, Leon J, Jeddeloh JA, McPherson JD: Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res. 2008, 18: 19-29.CrossRefPubMedPubMedCentral

64.

Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G: Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics. 2010, 11: 137-10.1186/1471-2164-11-137.CrossRefPubMedPubMedCentral

65.

Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA: Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011, 3: 75ra25-10.1126/scitranslmed.3001875.CrossRefPubMedPubMedCentral

66.

Sproul D, Nestor C, Culley J, Dickson JH, Dixon JM, Harrison DJ, Meehan RR, Sims AH, Ramsahoye BH: Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci USA. 2011, 108: 4364-4369. 10.1073/pnas.1013224108.CrossRefPubMedPubMedCentral

67.

International Human Epigenome Consortium. [http://www.ihec-epigenomes.org]

68.

Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009, 462: 315-322. 10.1038/nature08514.CrossRefPubMedPubMedCentral

69.

Goren A, Ozsolak F, Shoresh N, Ku M, Adli M, Hart C, Gymrek M, Zuk O, Regev A, Milos PM, Bernstein BE: Chromatin profiling by directly sequencing small quantities of immunoprecipitated DNA. Nat Methods. 2010, 7: 47-49. 10.1038/nmeth.1404.CrossRefPubMed

70.

Ernst J, Kellis M: Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010, 28: 817-825. 10.1038/nbt.1662.CrossRefPubMedPubMedCentral

71.

Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, Jager N, Gnirke A, Stunnenberg HG, Meissner A: Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol. 2010, 28: 1106-1114. 10.1038/nbt.1681.CrossRefPubMedPubMedCentral

72.

Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, Downey SL, Johnson BE, Fouse SD, Delaney A, Zhao Y, Olshen A, Ballinger T, Zhou X, Forsberg KJ, Gu J, Echipare L, O'Geen H, Lister R, Pelizzola M, Xi Y, Epstein CB, Bernstein BE, Hawkins RD, Ren B, Chung WY, Gu H, Bock C, Gnirke A, Zhang MQ, Haussler D, Ecker JR, Li W, Farnham PJ, Waterland RA, Meissner A, Marra MA, Hirst M, Milosavljevic A, Costello JF: Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010, 28: 1097-1105. 10.1038/nbt.1682.CrossRefPubMedPubMedCentral

73.

Dickinson LA, Dickinson CD, Kohwi-Shigematsu T: An atypical homeodomain in SATB1 promotes specific recognition of the key structural element in a matrix attachment region. J Biol Chem. 1997, 272: 11463-11470. 10.1074/jbc.272.17.11463.CrossRefPubMed

74.

de Belle I, Cai S, Kohwi-Shigematsu T: The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol. 1998, 141: 335-348. 10.1083/jcb.141.2.335.CrossRefPubMedPubMedCentral

75.

Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, ohwi-Shigematsu T: The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000, 14: 521-535.PubMedPubMedCentral

76.

Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008, 452: 187-193. 10.1038/nature06781.CrossRefPubMed

77.

Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010, 102: 1284-1296. 10.1093/jnci/djq243.CrossRefPubMed

78.

Cai S, Lee CC, Kohwi-Shigematsu T: SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet. 2006, 38: 1278-1288. 10.1038/ng1913.CrossRefPubMed

79.

Elsasser SJ, Allis CD, Lewis PW: Cancer. New epigenetic drivers of cancers. Science. 2011, 331: 1145-1146. 10.1126/science.1203280.CrossRefPubMed

80.

Roadmap Epigenomics Project. [http://www.roadmapepigenomics.org/data]

81.

Milosavljevic A: Putting epigenome comparison into practice. Nat Biotechnol. 2010, 28: 1053-1056. 10.1038/nbt1010-1053.CrossRefPubMedPubMedCentral

82.

The Cancer Genome Atlas Data Portal. [http://tcga-data.nci.nih.gov/tcga/]

Title: Epigenetics in breast cancer: what's new?
Authors: Yi Huang
Shweta Nayak
Rachel Jankowitz
Nancy E Davidson
Steffi Oesterreich
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 6/2011
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2925

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Variants on the promoter region of PTEN affect breast cancer progression and patient survival

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer

Breast cancer: current state and future promise

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer